Rates of chronic liver disease during pregnancy are rising partly due to MASLD and the downward trend of chronic viral hepatitis.

Women with cirrhosis and ascites experience worse health-related quality of life (HRQoL) than men, although no difference is seen in daily function, according to a study published in the August issue ...

Women with cirrhosis and ascites experience worse health-related quality of life (HRQoL) than men, although no difference is seen in daily function, according to a study published in the August issue ...

Terry's nails, a nail abnormality characterized by a white, frosted appearance with a reddish-brown band at the tip, can ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

In patients with hepatocellular carcinoma (HCC), hyponatremia is an independent predictor of increased rates of in-hospital mortality, with a greater impact reported among those with cirrhosis, ...

Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis. Adrenomedullin (ADM) ...

Enforcement of universal screenings would easily prevent sickness, expenses and death but enforcement isn’t easy.

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...